Watch as a doctor and his patient discuss
the UC journey

Dr Wolf speaks with a long time UC patient, Tim. Together they discuss his diagnosis and treatment journey, as well as the challenges that Tim has faced.

UC journey video thumbnail

Dr Wolf was compensated for his time. Tim is an actual patient. He was compensated for his time.
Individual results may vary.

One Capsule, Once Daily: The Only Oral Advanced Therapya That Can Be Used Before Biologics in Moderate-to-Severe UC Patients1-3

ZEPOSIA 7-Day Titration Schedule1

Zeposia 7-Day Titration Schedule. One Capsule, Once a Day, From the Start Zeposia 7-Day Titration Schedule. One Capsule, Once a Day, From the Start

One Capsule, Once a Day, From the Start

The ZEPOSIA Starter Pack is designed to make the titration easier to follow1

Eligible patients enrolled in ZEPOSIA 360 SupportTM, who have been cleared to begin treatment, and who have not received a sample from their provider, may be provided a Starter Kit that includes a 7-day Starter Pack and a 30-day supply of ZEPOSIA.

  • Initiate ZEPOSIA with a 7-day titration schedule. After initial titration, the recommended once-daily dosage of ZEPOSIA is 0.92 mg taken orally, starting on Day 8.1
  • An up-titration schedule should be used to reach the maintenance dose, as a transient decrease in heart rate and atrioventricular(AV) conduction delays may occur1
  • ZEPOSIA can be taken with or without food1

The ZEPOSIA Starter Pack is designed to make the titration easier to follow1

ZEPOSIA packages and bottle Recommended Dosage Pamphlet ZEPOSIA packages and bottle Recommended Dosage Pamphlet

Additional Dosing Considerations

  • If a dose of ZEPOSIA is missed during the first 2 weeks of treatment, reinitiate treatment using the titration regimen1
  • If a dose of ZEPOSIA is missed after the first 2 weeks of treatment, continue with the treatment as planned1
  • aAdvanced therapies include S1P, biologics, and JAKi.

Starting Patients on ZEPOSIA

Screening for All Patients Prior to First Dose1

  • Obtain blood work (within the last 6 months)
    • Complete blood count (CBC), including lymphocyte count (within the last 6 months or after discontinuation of prior UC therapy)
    • Transaminase and total bilirubin levels
  • Obtain a one-time electrocardiogram (ECG) to determine whether pre-existing conduction abnormalities are presentb

ZEPOSIA is contraindicated in patients who have the presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker.1

Screening for Select Patients Prior to First Dose1

  • If there is a history of uveitis, macular edema, or diabetes mellitus then ophthalmic evaluation of the fundus, including the macula must be completedc
  • If there is no documentation of history of varicella-zoster virus (VZV)/chicken pox, or documentation of a full course of vaccination, then test for antibodiesd
    • If live attenuated immunizations are required, administer at least 1 month prior to initiation

Evaluate current and prior medications before initiation of treatment1

Support provided by Bristol Myers Squibb at the Homes of Eligible Patientse

  • Blood work
  • ECG with cardiologist overread
  • Macular edema screening with licensed eye clinician overread
  • VZV antibody testing

The full Prescribing Information for ZEPOSIA
does not require routine lab monitoring unless clinically indicated

  • bIn patients with certain preexisting conditions, advice from a cardiologist should be sought—see Warnings and Precautions in Prescribing Information. ZEPOSIA was not studied in patients who had: Cardiac conduction or rhythm disorders, including sick sinus syndrome, significant QT prolongation (QTcF >450 msec in males, >470 msec in females), risk factors for QT prolongation, or other conduction abnormalities or cardiac condition that in the opinion of the treating investigator could jeopardize the patient's health.1
  • cPatients with a history of uveitis and patients with a history of diabetes mellitus are at increased risk of macular edema during ZEPOSIA therapy. The incidence of macular edema is also increased in patients with a history of uveitis. In addition to the examination of the fundus, including the macula, prior to treatment, patients with diabetes mellitus or a history of uveitis should have regular follow-up examinations.1
  • dVZV vaccination of antibody-negative patients is recommended prior to commencing treatment.1
  • eHome visits for initial routine medical tests are not available to patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or to patients living in Rhode Island.

AV=atrioventricular; BPM=beats per minute; CBC=complete blood count; ECG=electrocardiogram; HR=heart rate; JAKi=janus kinase inhibitor; QT=an extended interval between the heart contracting and relaxing; QTcF=corrected QT interval by Fridericia; UC=ulcerative colitis; VZV=varicella-zoster virus.

Get Your Patients Started on ZEPOSIA

Patient Start Form

Enroll patients in ZEPOSIA 360 SupportTM and help them get started on treatment.

Get Started With
Cover My Meds Icon

To begin the process online, click the button below to visit covermymeds.com

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.